Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1

Chemical Research in Toxicology

Volumn 25, Issue 8, 2012, Pages 1740-1751

  Wang, Kai ^a   Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 METHYL 4 NITROPHENYL) 5 FLUOROBENZOTHIAZOLE; 2 (3 METHYL 4 NITROSOPHENYL) 5 FLUOROBENZOTHIAZOLE; 2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; 2 (4 HYDROXYLAMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; 3 METHYL 4 NITROBENZOYL CHLORIDE; 5 FLUORO 2 (3 HYDROXY 4 METHOXYPHENYL)BENZOTHIAZOLE; 5 FLUORO 2 (3,4 DIMETHOXYPHENYL)BENZOTHIAZOLE; 5 FLUORO 2 (4 HYDROXY 3 METHOXYPHENYL)BENZOTHIAZOLE; BENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; BIS[4 FLUORO 2 (3 METHYL 4 NITROBENZOYL)AMINOPHENYL]DIFULFIDE; CYTOCHROME; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2S1; CYTOCHROME P450 2W1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTRANSFORMATION; CYTOTOXICITY; DEMETHYLATION; HUMAN; HYDROXYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION;

ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BIOCATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; HUMANS; KINETICS; MICROSOMES, LIVER; OXIDATION-REDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THIAZOLES;

EID: 84865249231     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx3001994     Document Type: Article

References (33)

1. Guengerich, F. P. (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity Chem. Res. Toxicol. 14, 611-650 (Pubitemid 32565712)
2. Guengerich, F. P. (2008) Cytochrome P450 and chemical toxicology Chem. Res. Toxicol. 21, 70-83 (Pubitemid 351219709)
3. Guengerich, F. P. (2005) Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemisty, 3 rd ed. (Ortiz de Montellano, P. R., Ed.) pp 377-530, Kluwer Academic/Plenum Press, New York.
4. Guengerich, F. P. and Cheng, Q. (2011) Orphans in the human cytochrome P450 superfamily: Approaches to discovering functions and relevance in pharmacology Pharmacol. Rev. 63, 684-699
5. Wu, Z. L., Sohl, C. D., Shimada, T., and Guengerich, F. P. (2006) Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1 Mol. Pharmacol. 69, 2007-2014 (Pubitemid 43894320)
6. Nishida, C. R., Lee, M., and Ortiz de Montellano, P. R. (2010) Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1 Mol. Pharmacol. 78, 497-502
7. Xiao, Y., Shinkyo, R., and Guengerich, F. P. (2011) Cytochrome P450 2S1 is reduced by NADPH-cytochrome P450 reductase Drug Metab. Dispos. 39, 944-946
8. Gomez, A., Karlgren, M., Edler, D., Bernal, M. L., Mkrtchian, S., and Ingelman-Sundberg, M. (2007) Expression of CYP2W1 in colon tumors: Regulation by gene methylation Pharmacogenomics 8, 1315-1325 (Pubitemid 350162848)
9. Gomez, A., Nekvindova, J., Travica, S., Lee, M. Y., Johansson, I., Edler, D., Mkrtchian, S., and Ingelman-Sundberg, M. (2010) Colorectal cancer-specific cytochrome P450 2W1: Intracellular localization, glycosylation, and catalytic activity Mol. Pharmacol. 78, 1004-1011
10. Edler, D., Stenstedt, K., Ohrling, K., Hallstrom, M., Karlgren, M., Ingelman-Sundberg, M., and Raynhammar, P. (2009) The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer-A pilot study Eur. J. Cancer 45, 705-712
11. Aiello, S., Wells, G., Stone, E. L., Kadri, H., Bazzi, R., Bell, D. R., Stevens, M. F., Matthews, C. S., Bradshaw, T. D., and Westwell, A. D. (2008) Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5- fluorobenzothiazole (PMX 610, NSC 721648) J. Med. Chem. 51, 5135-5139
12. Hutchinson, I., Chua, M. S., Browne, H. L., Trapani, V., Bradshaw, T. D., Westwell, A. D., and Stevens, M. F. (2001) Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl) benzothiazoles J. Med. Chem. 44, 1446-1455 (Pubitemid 32852121)
13. Brantley, E., Trapani, V., Alley, M. C., Hose, C. D., Bradshaw, T. D., Stevens, M. F., Sausville, E. A., and Stinson, S. F. (2004) Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells Drug Metab. Dispos. 32, 1392-1401 (Pubitemid 39564559)
14. Chua, M. S., Kashiyama, E., Bradshaw, T. D., Stinson, S. F., Brantley, E., Sausville, E. A., and Stevens, M. F. G. (2000) Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl) benzothiazole (DF 203, NSC 674495) in human breast cancer cells Cancer Res. 60, 5196-5203
15. Trapani, V., Patel, V., Leong, C. O., Ciolino, H. P., Yeh, G. C., Hose, C., Trepel, J. B., Stevens, M. F., Sausville, E. A., and Loaiza-Perez, A. I. (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5- fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells Br. J. Cancer 88, 599-605 (Pubitemid 36363371)
16. Omiecinski, C. J., Redlich, C. A., and Costa, P. (1990) Induction and developmental expression of cytochrome-P4501A1 messenger-RNA in rat and human tissues-Detection by the polymerase chain-reaction Cancer Res. 50, 4315-4321 (Pubitemid 20225671)
17. Kitada, M., Taneda, M., Itahashi, K., and Kamataki, T. (1991) 4 forms of cytochrome-P-450 in human fetal liver-Purification and their capacity to activate promutagens Jpn. J. Cancer Res. 82, 426-432
18. Leong, C. O., Suggitt, M., Swaine, D. J., Bibby, M. C., Stevens, M. F., and Bradshaw, T. D. (2004) In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles Mol. Cancer Ther. 3, 1565-1575 (Pubitemid 40136712)
19. 1 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines J. Med. Chem. 49, 179-185 (Pubitemid 43077331)
20. Tan, B. S., Tiong, K. H., Muruhadas, A., Randhawa, N., Choo, H. L., Bradshaw, T. D., Stevens, M. F., and Leong, C. O. (2011) CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells Mol. Cancer Ther. 10, 1982-1992
21. Turesky, R. J., Lang, N. P., Butler, M. A., Teitel, C. H., and Kadlubar, F. F. (1991) Metabolic-activation of carcinogenic heterocyclic aromatic-amines by human liver and colon Carcinogenesis 12, 1839-1845
22. Peng, L. J. and Turesky, R. J. (2011) Mass spectrometric characterization of 2-amino-1-methyl-6-phenylimidazo[4,5- b ]pyridine N -oxidized metabolites bound at Cys(34) of human serum albumin Chem. Res. Toxicol. 24, 2004-2017
23. Parikh, A., Gillam, E. M., and Guengerich, F. P. (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450 Nat. Biotechnol. 15, 784-788 (Pubitemid 27329483)
24. Guengerich, F. P. and Bartleson, C. J. (2007) Analysis and characterization of enzymes and nucleic acids. In Principles and Methods of Toxicology, 5 th ed. (Hayes, A. W., Ed.) pp 1981-2048, CRC Press, Boca Raton, FL.
25. Kim, D. and Guengerich, F. P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines Annu. Rev. Pharmacol. Toxicol. 45, 27-49 (Pubitemid 40261797)
26. Chun, Y. J., Kim, M. Y., and Guengerich, F. P. (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor Biochem. Biophys. Res. Commun. 262, 20-24 (Pubitemid 29412616)
27. Chakraborty, M., Jin, K. J., Brewer, S. C., Peng, H. L., Platz, M. S., and Novak, M. (2009) Indirect and direct detection of the 4-(benzothiazol-2-yl) phenylnitrenium ion from a putative metabolite of a model anti-tumor drug Org. Lett. 11, 4862-4865
28. Novak, M. and Chakraborty, M. (2011) Reactions of a putative metabolite of the model antitumor drug 2-(4-aminophenyl) benzothiazole with purines and pyrimidines J. Phys. Org. Chem. 24, 960-968
29. Chakraborty, M., Jin, K. J., Glover, S. A., and Novak, M. (2010) Characterization of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug J. Org. Chem. 75, 5296-5304
30. Humphreys, W. G., Kadlubar, F. F., and Guengerich, F. P. (1992) Mechanism of C8 alkylation of guanine residues by activated arylamines: Evidence for initial adduct formation at the N7 position Proc. Natl. Acad. Sci. U.S.A. 89, 8278-8282
31. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A., Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie, T. A. (2011) Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discovery 10, 292-306
32. Kim, D. H., Kadlubar, F. F., Teitel, C. H., and Guengerich, F. P. (2004) Formation and reduction of aryl and heterocyclic nitroso compounds and significance in the flux of hydroxylamines Chem. Res. Toxicol. 17, 529-536 (Pubitemid 38506987)
33. Xiao, Y. and Guengerich, F. P. (2012) Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. J. Lipid Res. DOI: 10.1194/jlr.M027185.